1 Schmid-Grendelmeier P et al. Swiss Expert Opinion on the Management of Chronic Spontaneous Urticaria. Derm Hel. 2016;28(8).
2 Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GWT, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–87.
3 Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipia S, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14(3):214–20.
4 Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59(8):869–73.
5 Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169–80.
6 Zuberbier T, Maurer M. Omalizumab for the treatment of chronic urticaria. Expert Rev Clin Immunol 2015;11(2):171-80.
7 Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacological mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:337–42.
8 Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365–72.
9 Prescribing information for Xolair
® (Omalizumab).
www.swissmedicinfo.ch
10 BAG [Bundesamt für Gesundheit: Federal Office of Public Health] direction.
11 Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19:491–8.
12 Zuberbier T, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1417–26.
13 Metzger H, et al. The receptor with high affinity for immunoglobulin E. Ann Rev Immunol. 1986;4:419–70.
14 Ishizaka T, et al. Biochemical analysis of initial triggering events of IgE-mediated histamine release from human lung mast cells. J Immunol. 1983;130:2357–62.
15 Dehlink E, Fiebiger E. The role of the high-affinity IgE receptor, FcepsilonRI, in eosinophilic gastrointestinal diseases. Immunol Allergy Clin North Am. 2009;29(1):159–70.
16 Magerl M, et al. Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy. 2010;Vol. 65(1):78–83.
17 Saini SS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015 Jan;135(1):67–75.
18 Maurer M, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticarial. N Engl J Med. 2013;368:924−35.
19 Kaplan A, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101−9.
20 Kang MJ, et al. The impact of chronic idiopathic urticaria on quality of life in korean patients. Ann Dermatol. 2009;21:226–9.